Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
7 results loaded, newest first. End of these results.
Standard BioTools has agreed to sell its Microfluidics business to Archimed, an investment firm focused on healthcare industries. The Microfluidics technology enables experiments at a scale not possible with traditional benchtop methods.
Standard BioTools Inc. has announced an agreement to sell its microfluidics business to Archimed. The deal is expected to close in approximately 30 days, during which time the microfluidics business will continue to operate as part of Standard BioTools.
Standard BioTools Inc. has announced an agreement to sell its microfluidics business to Archimed.
Standard BioTools has entered into a definitive agreement to divest its Microfluidics business to ARCHIMED. The transaction is anticipated to be finalized within approximately 30 days.
Standard BioTools Inc. agreed to sell its Microfluidics business to ARCHIMED. The closing is expected in approximately 30 days, subject to customary conditions.
Standard BioTools entered into a definitive agreement to sell its Microfluidics business to ARCHIMED.
Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED. Closing is targeted in about 30 days, subject to customary closing conditions, with Microfluidics operations remaining at Standard BioTools until the deal closes.